Palisade Bio announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 inhibitor prodrug in development for patients affected by UC. These findings demonstrated that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC. The enzymatic activity in stool samples was assessed using LC-MS analysis with all stool samples meeting the target conversion rate within a 24-hour period. The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time. The study was conducted in collaboration with Altasciences based in Montreal, QC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio to Participate in the Virtual Investor Lunch Break Event
- Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
- Palisade Bio presents development overview of PALI-2108
- Palisade Bio Inc trading halted, news pending
- Palisade Bio Announces 1-for-15 Reverse Stock Split